See every side of every news story
Published loading...Updated

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

  • CStone Pharmaceuticals submitted a Phase Ib clinical trial application in Australia for CS5001, targeting first-line treatment for diffuse large B-cell lymphoma in combination with R-CHOP.
  • The trial aims to reshape treatment standards for diffuse large B-cell lymphoma and expand CS5001's use across lymphoma stages and solid tumors.
  • CS5001 has shown promising data in monotherapy for lymphomas, and its combination previously achieved a significant complete response rate.
Insights by Ground AI
Does this summary seem wrong?

38 Articles

All
Left
3
Center
11
Right
4
The Laconia Daily SunThe Laconia Daily Sun
+37 Reposted by 37 other sources

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape.CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 61% of the sources are Center
61% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Charleston Gazette-Mail broke the news in Charleston, United States on Thursday, March 6, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.